Pulmatrix
Massachusetts, United States · Healthcare · 2 employees
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE technology, which enables better delivery of drugs to the lungs. The company is dedicated to improving the lives of patients with respiratory diseases and advancing the field of inhaled therapies.
Funding history
- Series seed — $1.0M — Apr 2026
- Series pre-seed — $45K — Jul 2021
- Funding Round — Undisclosed — Feb 2021
- Funding Round — Undisclosed — Jul 2020
- Funding Round — $8.1M — Apr 2020
Recent signals
- May 15, 2026: Acquired Pulmatrix to merge with Eos SENOLYTIX in 2026
- Apr 15, 2026: Raised $1.0M in Series seed
- Mar 26, 2026: Acquired Pulmatrix to merge with Eos SENOLYTIX for healthspan
- Oct 16, 2025: SEC 8-K (2.02): On October 16, 2025, Pulmatrix, Inc. announced their financial results for the third fiscal quarter ended September 30, 2025. This press release also included a corporate update and is detailed in Exhibit 99.1 attached to the filing. While the financial amounts are not specified in the excerpt, such disclosures typically highlight revenue, net income or loss, and other critical financial metrics that impact stakeholder perceptions. The corporate update may address strategic initiatives or operational changes that could influence future performance, although specific content is not included in this excerpt.
- Jul 20, 2021: Raised $45K in Series pre-seed
- Feb 23, 2021: Raised Undisclosed
- Jul 20, 2020: Raised Undisclosed
- Apr 24, 2020: Raised $8.1M
See plans & pricing → Track Pulmatrix’s funding, hiring, and signals — with verified contacts — on Fundz.